Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091458 | 1.00 | ACHE (0.42) | ACHEMEN1KMT2AMAPK14CYP3A4 | |
| SCHEMBL4094675 | 0.90 | MAPK1 (0.34) | ACHEKMT2AMAPK14 | |
| SCHEMBL4090559 | 0.89 | ACHE (0.37) | ACHEMEN1KMT2AMAPK14CYP3A4 | |
| SCHEMBL4090269 | 0.89 | ACHE (0.37) | ACHEMEN1KMT2AMAPK14CYP3A4 | |
| SCHEMBL4098877 | 0.86 | CCNT1 (0.40) | MAPK14 | |
| SCHEMBL4098900 | 0.85 | MAPK14 (0.36) | MEN1KMT2AMAPK14 | |
| SCHEMBL4091456 | 0.85 | MAPK14 (0.36) | MEN1KMT2AMAPK14CYP3A4CYP2C9 | |
| SCHEMBL4084081 | 0.85 | IRAK4 (0.41) | ACHEMEN1KMT2AMAPK14CYP3A4 | |
| SCHEMBL4097183 | 0.85 | IRAK4 (0.41) | ACHEMEN1KMT2AMAPK14CYP3A4 | |
| SCHEMBL4100701 | 0.83 | ACHE (0.48) | ACHEMEN1KMT2ACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | claimed |
| EP-1727821-A1 | SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Amgen Inc. (US) | 2006-12-06 | — | — | EP | claimed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | claimed |
| WO-2005070934-A1 | SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | ACHE 2707/4885MEN1 255/4885KMT2A 2985/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | ACHE 2633/4885MEN1 344/4885KMT2A 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.